Mer­ck makes first big splash for Alzheimer’s drug R&D since 2017 fail, ink­ing re­search pact with Cere­vance

3 years ago
Deals

Ko­di­ak man­ages to score a win for its Eylea ri­val — but the ma­jor test is still ahead

3 years ago
R&D

Karuna looks to build on pos­i­tive schiz­o­phre­nia da­ta with one of the biggest pub­lic rais­es this year

3 years ago
Financing

CorMedix hit with sec­ond CRL for an­ti­fun­gal treat­ment, cit­ing man­u­fac­tur­ing and API is­sues

3 years ago
FDA+
Manufacturing

Why non-opi­oid pain drugs keep fail­ing — and what's next for the field

3 years ago
R&D
In Focus

US to stop sup­ply­ing Lil­ly's mAb for Covid-19 this month as com­mer­cial mar­ket awaits

3 years ago
Pharma
Coronavirus

Math­ai Mam­men makes an abrupt ex­it as head of the big R&D group at J&J

3 years ago
People

No­vavax shares shred­ded as Covid vac­cine sales fall more than 90% in Q2

3 years ago
Pharma

In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

3 years ago
Deals
Pharma

De­spite falling Covid-19 sales, BioN­Tech main­tains '22 sales guid­ance

3 years ago
Pharma

With drug pric­ing al­most done, Con­gress looks to wrap up FDA user fee leg­is­la­tion

3 years ago
FDA+
Law

GSK and IQVIA launch plat­form of US vac­ci­na­tion da­ta, show­ing drop in adult rates

3 years ago
Pharma

Ab­b­Vie sur­veys emo­tion­al im­pact of chron­ic leukemia con­di­tion, finds 'roller coast­er' of emo­tions

3 years ago
Pharma
Marketing

As­traZeneca and Dai­ichi Sankyo sprint to mar­ket af­ter FDA clears En­her­tu in just two weeks

3 years ago
Pharma
FDA+

FDA's vac­cine ad­comm to re­view first fe­cal trans­plant to treat C. dif­fi­cile in­fec­tions

3 years ago
Pharma
FDA+

Q&A: Astel­las' re­tir­ing head of de­vel­op­ment re­flects on gene ther­a­py deaths

3 years ago
People
Cell/Gene Tx

UniQure halts high-dose treat­ments of Hunt­ing­ton's drug af­ter 3 pa­tients hos­pi­tal­ized — shares tank

3 years ago
R&D
Cell/Gene Tx

Sarep­ta li­cens­es next-gen AAV tech from Broad In­sti­tute in deal cov­er­ing five in­di­ca­tions — in­clud­ing Duchenne

3 years ago
Deals

Pfiz­er and My­ovant’s en­dometrio­sis pain drug Myfem­bree gets an­oth­er FDA nod

3 years ago
Pharma
FDA+

Clo­vis says it needs mon­ey af­ter re­verse split vot­ed down; Cin­Cor touts PhII da­ta for hy­per­ten­sion drug

3 years ago
News Briefing

Rea­ta con­tin­ues to hit FDA road­blocks with its Friedre­ich’s atax­ia can­di­date, not­ing reg­u­la­tor 'con­cern­s'

3 years ago
R&D
Pharma

Karuna's schiz­o­phre­nia drug pass­es a close­ly-watched PhI­II test, will head to FDA in mid-2023

3 years ago
R&D

Eli Lil­ly eyes growth out­side In­di­ana in wake of new abor­tion law — and New Jer­sey is ready

3 years ago
People
Pharma

Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

3 years ago
Deals
First page Previous page 477478479480481482483 Next page Last page
A service from the Financial Times